Zeenat Qureshi Stroke Institute, 519 2nd Street North, St. Cloud, MN, 56303, USA.
University of Illinois and Mercyhealth, Rockford, IL, USA.
Neurocrit Care. 2018 Aug;29(1):54-61. doi: 10.1007/s12028-018-0502-3.
To determine the effectiveness of prolonged microcatheter-based local thrombolytic infusion in treatment of patients with cerebral venous thrombosis who achieved no or suboptimal recanalization with transvenous endovascular treatment.
Data collection: Prospectively registries supplemented by retrospective review.
Three hospitals with tertiary referral base.
Patients who underwent transvenous endovascular treatment for cerebral venous thrombosis.
Prolonged microcatheter-based local thrombolytic infusion of alteplase at the rate of 0.5-1 mg/h in patients in whom initial angiographic outcome was deemed suboptimal, either due to incomplete or no recanalization.
Serial angiograms were performed to assess treatment response as follows: grade I, partial recanalization of one or more occluded dural sinuses with improved flow or visualization of branches; grade II, complete recanalization of one sinus but persistent occlusion of the other sinuses (A-no residual flow, B-nonocclusive flow); grade III, complete recanalization. Clinical outcome was determined at 1-3 months using modified Rankin scale. A total of 14 patients underwent 15 transvenous endovascular treatments. Initial treatment was considered suboptimal in 12/15 procedures due to no recanalization in five (grade 0), partial recanalization (grade I) in four, complete recanalization of one sinus but persistent occlusion of the other sinuses (grade 2A in two and 2B in one). A prolonged microcatheter-based local recombinant tissue plasminogen activator infusion was used following ten of the 15 procedures for a median duration of 18 h (range 13-22 h). Follow-up angiography demonstrated complete recanalization in four procedures and improvement in grades of partial recanalization in six procedures (final grades 2A in three and 2B in three procedures). None of the patients developed new symptomatic intracranial hemorrhage associated with local thrombolytic infusion. At follow-up, patients in five of ten procedures had achieved a modified Rankin scale of 0 and one patient had achieved a score of 1 (no neurological deficits but had residual headaches).
Prolonged microcatheter-based local thrombolytic infusion appeared to be effective treatment in patients who have suboptimal response to acute transvenous endovascular treatment without any additional adverse events.
旨在评估微导管持续局部溶栓灌注治疗急性经静脉血管内治疗后颅内静脉血栓形成患者的有效性,这些患者初始血管造影结果显示再通不完全或未再通。
数据收集:前瞻性登记研究,并进行回顾性分析。
三家具有三级转诊基地的医院。
接受经静脉血管内治疗的颅内静脉血栓形成患者。
对于初始血管造影结果不理想(即再通不完全或未再通)的患者,采用微导管持续局部溶栓灌注阿替普酶,速度为 0.5-1mg/h。
连续进行血管造影以评估治疗反应,分级如下:I 级,一条或多条闭塞硬脑膜窦部分再通,血流或分支显影改善;II 级,一条窦完全再通,但其他窦仍闭塞(A 无残留血流,B 非阻塞性血流);III 级,完全再通。采用改良 Rankin 量表于治疗后 1-3 个月评估临床结局。共 14 例患者行 15 次经静脉血管内治疗。15 次治疗中有 12 次初始治疗被认为效果不理想,5 次(0 级)无再通,4 次部分再通(I 级),2 条窦完全再通但另 2 条窦持续闭塞(2A 级 2 次,2B 级 1 次)。15 次治疗中有 10 次在血管成形术后行微导管持续局部重组组织型纤溶酶原激活剂灌注治疗,中位时间 18 小时(范围 13-22 小时)。随访血管造影显示 4 次完全再通,6 次部分再通程度改善(最终分级为 2A 级 3 次,2B 级 3 次)。局部溶栓治疗未导致任何与出血相关的新的症状性颅内出血。10 次治疗中有 5 次在随访时改良 Rankin 量表评分为 0,1 次评分为 1(无神经功能缺损,但仍有头痛残留)。
对于急性经静脉血管内治疗效果不理想的患者,微导管持续局部溶栓灌注治疗似乎是一种有效的治疗方法,且无额外不良事件发生。